We are live on ! Find out more
ACM

Athyrium Capital Management Portfolio holdings

AUM $8.69M
1-Year Est. Return 34.58%
This Fund
S&P 500
This Quarter Est. Return
-0.81%
1 Year Est. Return
-34.58%
3 Year Est. Return
-25.1%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$68.8M
AUM Growth
-$44.7M
Cap. Flow
-$45.9M
Cap. Flow %
-66.7%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RVLP
RVL Pharmaceuticals plc Ordinary Shares
RVLP
+$1.26M

Sector Composition

Rank Sector Weight
1 Healthcare 32.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIOR
1
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$14.8M 21.44%
1,092,976
– –
PBYI icon
2
Puma Biotechnology
PBYI
$398M
$7.76M 11.27%
1,792,114
– –
RVLP
3
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
– –
-14,600,444
Closed -$1.26M

Similar funds

BGC
Birch Grove Capital New York $9.51M AUM 0.22% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
JDR
Jay D. Rosenbaum $6.69M AUM 4.68% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
KIM
Kaizen Investment Management Singapore $6.23M AUM
RJTCONH
Raymond James Trust Company of New Hampshire Portsmouth, New Hampshire $12.1M AUM 28.84% 1-Year Est. Return
HSC
Harbor Spring Capital New York $12.3M AUM
HVM
Harvest Volatility Management Norwalk, Connecticut $4.39M AUM 13.08% 1-Year Est. Return

Athyrium Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Athyrium Capital Management held 4 positions worth $68.8M, down 39% from $114M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Athyrium Capital Management withdrew a net $45.9M in Q4 2023, closing 1 position. Its most notable exit was RVL Pharmaceuticals plc Ordinary Shares, an estimated $1.26M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 26% a quarter earlier.

  • Athyrium Capital Management fully exited RVL Pharmaceuticals plc Ordinary Shares in Q4 2023, selling an estimated $1.26M.
  • Athyrium Capital Management's ten largest holdings make up 100% of its $68.8M portfolio in Q4 2023.
  • Athyrium Capital Management opened 0 new positions and closed 1 in Q4 2023.
  • Athyrium Capital Management's portfolio value fell 39% quarter-over-quarter to $68.8M.

Based on Athyrium Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.